

### Supplementary materials

#### Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus.

Authors:

Coziana Ciurtin<sup>1,2\*</sup>, Junjie Peng<sup>1,2</sup>, Yiming Gao<sup>3</sup>, Misato Niwa<sup>3</sup>, Stacy P. Ardoin<sup>4</sup>, Laura E. Schanberg<sup>5</sup>, Laura Lewandowski<sup>6</sup>, Elizabeth C Jury<sup>2</sup>, George A Robinson<sup>1,2</sup>

**Supplementary Table.** CVD-risk stratification of the placebo vs. statin arms of the APPLE cohort at the end of the trial (36 months). The CVD-risk stratification was compared against the CIMT progression over 36 months, as published before (5).

*Legend: CIMT= carotid intima media thickness; CVD= cardiovascular disease; N= number of children and young people with cSLE with complete data available to calculate various CVD-risk scores.*

<b>cSLE patient cohorts stratified based on CIMT progression rates over 36 months in the placebo (high vs. low) and statin (high vs. moderate vs. low) arms (6)</b>	<b>The placebo group (N=60) at 36M</b>	<b>The statin group (N=61) at 36M</b>
	was stratified as: 41.7% low and 58.3% high CVD-risk	was stratified as: 24.6% low, 39.3% moderate, and 36.1% high CVD-risk
<b>QRISK-3 score (N)</b>	<b>51</b>	<b>55</b>
Very low QRISK-3 risk <5%	44 (86.3%)	46 (83.6%)
Low QRISK-3 risk = 5-9.9%	5 (9.8%)	7 (12.7%)
Moderate QRISK-3 risk = 10-19.9%	1 (2.0%)	1 (1.8%)
High QRISK-3 risk >20%	1 (2.0%)	1 (1.8%)
<b>FRS score (N)</b>	<b>51</b>	<b>55</b>
Very low FRS <5%	51 (100%)	55 (100%)
Low FRS = 5-9.9%	0	0
Moderate FRS =10-19.9%	0	0
High FRS >20%	0	0
<b>ASCVD score (N)</b>	<b>32</b>	<b>23</b>
Low ASCVD risk <5%	31 (96.9%)	21 (91.3%)
Moderate ASCVD risk = 5-7.4%	0 (0%)	0 (0%)
High ASCVD risk = 7.5-20%	1 (3.1%)	2 (8.7%)

PDAY score (N)	51	55
Very low PDAY score <2 points	32 (62.7%)	29 (52.7%)
Low PDAY score = 2-5 points	10 (19.6%)	15 (27.3%)
Moderate PDAY score = 6-10 points	7 (13.7%)	9 (16.4%)
High PDAY score >10 points	2 (3.9%)	2 (3.6%)

### Supplementary Figure:

UCL cohort stratification based on 6-metabolite signature of high CIMT progression in the APPLE trial (5).

*Legend: Total-CE = total cholesteryls esters; Total-C = total cholesterol; M-LDL-FC = free cholesterol in medium low-density lipoproteins (LDL); S-LDL-PL = phospholipids in small LDL; S-LDL-C = cholesterol in small LDL; S-LDL-L = total lipids in small LDL*

